{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:49:37Z","timestamp":1790225377201,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vaccine.2018.07.076","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T08:32:12Z","timestamp":1533889932000},"page":"5781-5788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12\u201315\u202fmonths: A phase III, randomized, non-inferiority trial"],"prefix":"10.1016","volume":"36","member":"78","reference":[{"issue":"62","key":"10.1016\/j.vaccine.2018.07.076_b0005","first-page":"1","article-title":"Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"2013","author":"McLean","year":"2013","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.vaccine.2018.07.076_b0010","unstructured":"World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011; 86: 301\u201316."},{"key":"10.1016\/j.vaccine.2018.07.076_b0015","unstructured":"World Health Organization. Measles vaccines: WHO position paper \u2013 April 2017. Wkly Epidemiol Rec 2017; 92: 205\u201327."},{"key":"10.1016\/j.vaccine.2018.07.076_b0020","unstructured":"World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2007; 82: 51\u201360."},{"key":"10.1016\/j.vaccine.2018.07.076_b0025","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6643a3","article-title":"Vaccination coverage among children aged 19\u201335 months \u2013 United States, 2016","volume":"66","author":"Hill","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.076_b0030","unstructured":"World Health Organization. Immunization, Vaccines and Biologicals. Data, statistics and graphics. 2017. Accessed 24\/01\/2018. <http:\/\/www.who.int\/immunization\/monitoring_surveillance\/data\/en\/>."},{"key":"10.1016\/j.vaccine.2018.07.076_b0035","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jama.2016.1353","article-title":"Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis","volume":"315","author":"Phadke","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.07.076_b0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa1703309","article-title":"Effectiveness of a third dose of MMR vaccine for mumps outbreak control","volume":"377","author":"Cardemil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.07.076_b0045","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamapediatrics.2017.1695","article-title":"Public health and economic consequences of vaccine hesitancy for measles in the United States","volume":"171","author":"Lo","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2018.07.076_b0050","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.vaccine.2014.01.094","article-title":"Impact of measles national vaccination coverage on burden of measles across 29 Member States of the European Union and European Economic Area, 2006\u20132011","volume":"32","author":"Colzani","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.076_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.puhe.2017.07.022","article-title":"Tackling mumps in a public health setting: loopholes in disease surveillance","volume":"152","author":"Gopakumar","year":"2017","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2018.07.076_b0060","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.35.30605","article-title":"Ongoing mumps outbreak in Israel, January to August 2017","volume":"22","author":"Indenbaum","year":"2017","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.07.076_b0065","unstructured":"European Medicines Agency. Priorix. Annex III: Summary of product characteristics, labelling and package leaflet. 2012. Accessed 24\/01\/2018. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Priorix_30\/WC500124199.pdf>."},{"key":"10.1016\/j.vaccine.2018.07.076_b0070","unstructured":"PATH Vaccine and Pharmaceutical Technologies Group. Summary of stability data for licensed vaccines. 2012. Accessed 24\/01\/2018. <https:\/\/www.path.org\/publications\/files\/TS_vaccine_stability_table.pdf>."},{"key":"10.1016\/j.vaccine.2018.07.076_b0075","doi-asserted-by":"crossref","unstructured":"World Health Organization. Guidelines on stability evaluation of vaccines. Biologicals 2009; 37: 424\u201334.","DOI":"10.1016\/j.biologicals.2009.08.017"},{"key":"10.1016\/j.vaccine.2018.07.076_b0080","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1080\/21645515.2017.1309486","article-title":"Two-year antibody persistence in children vaccinated at 12\u201315 months with a measles-mumps-rubella virus vaccine without human serum albumin","volume":"13","author":"Berry","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.076_b0085","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2018.07.076_b0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2018.07.076_b0095","doi-asserted-by":"crossref","first-page":"e007202","DOI":"10.1136\/bmjopen-2014-007202","article-title":"Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial","volume":"5","author":"Lalwani","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2018.07.076_b0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.07.076_b0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jpids\/piu081","article-title":"Safety and immunogenicity of human serum albumin-free MMR Vaccine in US children aged 12\u201315 months","volume":"4","author":"Mufson","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.07.076_b0110","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2165\/00003495-200363190-00012","article-title":"Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.07.076_b0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-0934(99)00019-1","article-title":"Assay of humoral immunity to mumps virus","volume":"79","author":"Pipkin","year":"1999","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.07.076_b0120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1086\/590115","article-title":"Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak","volume":"198","author":"Rubin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.076_b0125","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1128\/JCM.43.9.4847-4851.2005","article-title":"Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays","volume":"43","author":"Mauldin","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.07.076_b0130","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1016\/j.vaccine.2016.06.063","article-title":"Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection","volume":"34","author":"Gouma","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.076_b0135","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/infdis\/jir526","article-title":"Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity","volume":"204","author":"Cortese","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.076_b0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CVI.00621-13","article-title":"Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method","volume":"21","author":"Latner","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.07.076_b0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T23:43:38Z","timestamp":1571701418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0264410X1831096X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12\u201315\u202fmonths: A phase III, randomized, non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}